- Home
- ADXN vs POM Comparison
ADXN vs POM Comparison
Compare ADXN & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | POM |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Switzerland | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADXN | POM |
|---|---|---|
| Price | $2.93 | $1.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 4.0M |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $767.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $0.06 |
| 52 Week High | $10.43 | $6.43 |
Technical Indicators
Market Signals| Indicator | ADXN | POM |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 65.33 |
| Support Level | $2.60 | $0.28 |
| Resistance Level | $3.25 | N/A |
| Average True Range (ATR) | 0.19 | 0.48 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 47.48 | 59.48 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.